Sly Saint
Senior Member (Voting Rights)
BRIDGEWATER, N.J., May 13, 2020 /PRNewswire/ -- JOGOHEALTH Inc., a Bridgewater, New Jersey based privately held digital therapeutics company focused on the development and commercialization of treatments for neuromuscular (NM) and chronic pain conditions today announced that it will launch a study on COVID-19 related Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS).
According to the patient advocacy group Solve ME/CFS Initiative, nearly 35% of COVID-19 patients are experiencing ME/CFS symptoms post infection. Since the onset of ME/CFS usually follows a viral infection, experts estimate up to 3,570,000 new ME/CFS cases following the COVID-19 pandemic. This would more than double the existing cases of ME/CFS in the United States in just 36 months, according to Solve ME/CFS Initiative.
"The science behind JOGO has shown to work for Fibromyalgia in many peer reviewed studies. Fibromyalgia and CFS/ME are both illnesses characterized by extreme amounts of fatigue. In fact, the conditions seem to be so intertwined that the medical community continues to debate whether fibromyalgia fatigue is simply a different expression of the same disorder that causes CFS. So, we approached some of the top experts in this field and the researchers were convinced, JOGO is a potential candidate for ME/CFS," said Siva Nadarajah, Co-Founder and President of JOGO Health Inc.
"We are excited by the opportunity to help patients, during post COVID-19 recovery phase. There are no treatments for ME/CFS yet – CDC has shown special interest in this condition as it impacts patients' return to normal life. In a befitting honor to the memory of Florence Nightingale – who suffered from ME/CFS – her birthday, May12th, is marked as World ME/CFS Day," said Sanjai Murali, Founder and CEO of JOGO Health Inc.
According to CDC, prior to COVID-19, ME/CFS affected up to 2.5 million Americans. The Arthritis Foundation estimates that 50 to 70 percent of people with fibromyalgia also fit the criteria of ME/CFS
https://www.prnewswire.com/news-rel...chronic-fatigue-syndrome-study-301058714.html